It is also the eighth installment in a series on hepatitis D virus, a virusoid-like pathogen that causes serious human disease. You may read the others on Forbes or www.williamhaseltine.com.

The American Gastroenterology Association (AGA) issued a new clinical guideline recommending antiviral drugs for patients at high risk for hepatitis B reactivation. (Gastroenterology) Researchers ...

Recent data report that HDV IgM levels correlate with histological inflammatory activity, and support the use of quantitative anti-HDV IgM as an indicator of disease activity in hepatitis D.

Patients with HIV and hepatitis B coinfection are at an increased risk for hepatitis D. Patients with hepatitis D have an increased risk for liver-related complications and mortality. Patients ...

Gilead Sciences has been knocked back in its quest to bring the first drug therapy for hepatitis D virus (HDV) to the US market, after the FDA rejected its marketing application. News of the ...

Infection with hepatitis D viruses causes severe inflammation of the liver. An MHH team has now identified a marker on natural killer cells that is influenced by the anti-inflammatory ...

The Philadelphia Department of Public Health has released its 2023 Annual Report on Hepatitis B, C, and D in the city. The ...

There are currently no approved treatments for chronic hepatitis D in the United States and most countries around the world. "Chronic hepatitis delta is the most aggressive form of viral hepatitis and ...

There are five kinds of hepatitis. Each has different causes, with one commonality: Hepatitis causes your liver to get inflamed. Hepatitis disease can also sometimes be spread through sexual contact.

The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to brelovitug (BJT-778) for the treatment of chronic hepatitis delta (CHD).

No writing assistance was utilized in the production of this manuscript. Hepatitis D virus (HDV) infection occurs in individuals positive for the HBV surface antigen (HBsAg). HDV is present ...